<DOC>
	<DOCNO>NCT01659606</DOCNO>
	<brief_summary>Dyskeratosis congenita disease affect numerous part body , typically cause failure blood system . Lung disease , liver disease cancer frequent cause illness death . Bone marrow transplantation ( BMT ) cure blood system make lung liver disease risk cancer worse , DNA damage agent alkylators radiation typically used procedure . Based biology DC , hypothesize may possible avoid DNA damage agent patient DC , still successful BMT . In protocol test whether regimen avoids DNA alkylators radiation permit successful BMT without compromise survival patient DC .</brief_summary>
	<brief_title>Radiation- Alkylator-free Bone Marrow Transplantation Regimen Patients With Dyskeratosis Congenita</brief_title>
	<detailed_description>Dyskeratosis congenita ( DC ) inherit multisystem disorder , classically present clinical triad skin pigment abnormality , nail dystrophy , oral leukoplakia . DC part spectrum telomere biology disorder , include form inherited idiopathic aplastic anemia , myelodysplastic syndrome , pulmonary fibrosis congenital diseases Hoyeraal-Hreidarsson syndrome Revesz syndrome . Progressive bone marrow failure ( BMF ) occur 80 % patient 30 year age primary cause morbidity mortality , follow pulmonary failure malignancy . Allogeneic hematopoietic cell transplantation ( HCT ) curative hematological defect , several study demonstrate poor outcome DC patient due increase early late complication . A predisposition pulmonary failure , vascular disease secondary malignancy may contribute high incidence fatal complication follow HCT DC patient , provide impetus reduce exposure chemotherapy radiotherapy preparative regimen . Recent study suggest fludarabine-based conditioning regimen provide stable engraftment may avoid toxicity see HCT DC , study date limit case report , retrospective study single prospective trial . In study , propose prospectively evaluate efficacy fludarabine- antibody-based conditioning regimen HCT DC patient , goal maintain donor hematopoiesis transfusion independence decrease early late complication HCT DC .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Dyskeratosis Congenita</mesh_term>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<mesh_term>Intellectual Disability</mesh_term>
	<mesh_term>Microcephaly</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Alkylating Agents</mesh_term>
	<criteria>Bone marrow hypocellular age Moderate severe aplastic anemia define one following : peripheral blood neutrophil &lt; 0.5 x 10^9/L ; platelet &lt; 30 x 10^9/L platelet transfusion dependence ; reticulocytes &lt; 50 x 10^9/L anemic patient red cell transfusion dependence Diagnosis dyskeratosis congenita base clinical triad abnormality skin pigmentation , nail dystrophy , oral leukoplakia ; OR one clinical triad presence two associated feature ; OR pathogenic mutation DKC1 , TERC , TERT , NOP10 , NHP2 , TCAB1 , TINF2 , CTC1 , PARN , RTEL1 , ACD report CLIAapproved laboratory ; OR ageadjusted mean telomere length &lt; 1 % ile peripheral blood lymphocyte report CLIAapproved laboratory ; OR HoyeraalHreidarsson syndrome ; OR Revesz syndrome Availability relate unrelated donor 7/8 8/8 match HLAA , B , C , DRB1 . Patient and/or legal guardian must able sign inform consent . Donor must provide marrow allograft . Diagnosis Fanconi anemia must exclude mitomycin C diepoxybutane chromosomal breakage test peripheral blood CLIAapproved laboratory ( required patient genetic mutation consistent DC ) Adequate renal function glomerular filtration rate equal great 30 ml/min/1.73 m2 Clonal cytogenetic abnormality associate MDS AML bone marrow examination . Karnofsky/Lansky performance status &lt; 40 . Uncontrolled bacterial , viral fungal infection . Positive test human immunodeficiency virus ( HIV ) . Pregnancy breastfeed . Known severe lifethreatening allergy intolerance fludarabine , alemtuzumab , cyclosporine , mycophenolate mofetil . Positive patient antidonor HLA antibody , deem clinically significant . Prior allogeneic marrow stem cell transplantation . Prior solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dyskeratosis congenita</keyword>
	<keyword>bone marrow failure</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>reduce intensity conditioning</keyword>
	<keyword>campath</keyword>
	<keyword>fludarabine</keyword>
	<keyword>telomere</keyword>
</DOC>